Dr. Reddy's Laboratories has announced the opening of a special window for re-lodgement of transfer requests for physical shares through a newspaper advertisement published on March 12, 2026. The pharmaceutical company has taken this step to facilitate shareholders holding physical share certificates who need to complete their transfer processes.

Regulatory Compliance and Communication

The company published the advertisement in two prominent newspapers - Business Standard and Nava Telangana - in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to make certain disclosures through newspaper publications to ensure transparency and proper communication with stakeholders.

Stock Exchange Notification

Dr. Reddy's Laboratories formally communicated this development to both major stock exchanges where its shares are listed. The company sent official notifications to the National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) and BSE Limited (Scrip Code: 500124), providing copies of the newspaper advertisements as required under regulatory guidelines.

Corporate Communication Details

The official communication was signed by K Randhir Singh, who holds the positions of Company Secretary, Compliance Officer & Head-CSR at Dr. Reddy's Laboratories. The digital signature was applied on March 12, 2026, at 21:12:52 +05'30', ensuring the authenticity and timing of the corporate disclosure.

Company Information

Dr. Reddy's Laboratories Ltd. is headquartered at 8-2-337, Road No. 3, Banjara Hills, Hyderabad – 500 034, Telangana, India. The company operates under CIN: L85195TG1984PLC004507 and maintains its corporate website at www.drreddys.com . This special window initiative demonstrates the company's commitment to facilitating smooth share transfer processes for its physical shareholders while maintaining full regulatory compliance.

Dr. Reddy's Laboratories Limited has announced the allotment of 10,275 equity shares to eligible employees under its Employee Stock Options Plans (ESOPs) on March 12, 2026. The pharmaceutical company issued this disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Share Allotment Details

The company allotted the equity shares pursuant to the exercise of stock options by employees under two established schemes. The allotment covers shares under both Dr. Reddy's Employees Stock Options Scheme, 2002 and Dr. Reddy's Employees ADR Stock Options Scheme, 2007.

Updated Share Capital Structure

Following this allotment, Dr. Reddy's Laboratories' share capital structure has been updated to reflect the additional equity shares issued to employees.

The company noted a difference of 1,000 shares between issued and paid-up capital due to forfeited shares of Re. 1/- each in September 1988 on account of non-payment of allotment money.

Regulatory Compliance and Share Characteristics

The newly allotted shares are identical in all respects to the existing equity shares and rank pari passu with them. The shares carry no lock-in restrictions and are eligible for immediate trading. The company has listed its shares on multiple exchanges including BSE Limited, National Stock Exchange of India Limited, New York Stock Exchange Inc. (ADRs), and NSE IFSC Limited (ADRs).

The ESOP schemes under which these shares were allotted were originally established under the erstwhile SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999, and now comply with the provisions of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The disclosure was signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR.